Fig. 3From: LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLCLCL161 and paclitaxel synergize to reduce cell viability in NSCLC cells. A549 and H460 lung cancer cells were treated for 48 h with the indicated concentrations of LCL161 (a) or paclitaxel (b). Cells were treated for 48 h with the indicated concentrations of LCL161 and paclitaxel (c) or for the indicated times with 10 μM LCL161 and/or 10 μM paclitaxel (d). Cell viability was determined by the MTT assay. Data are represented as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001Back to article page